Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, preclinical, and clinical evidence without systematic review methodology
PubMed 41953516 · doi:10.1039/d5md01173f
What was done
This review synthesized mechanistic, preclinical, and clinical literature evaluating N-acetylcysteine (NAC) and its lipophilic derivative N-acetylcysteine amide (NACA) across pulmonary, hepatic, neuropsychiatric, metabolic, cardiovascular, and oncologic conditions.
What was found
The abstract provides no quantitative data or effect sizes. It qualitatively describes NAC as modulating glutathione metabolism, redox-sensitive signaling, immune checkpoints, ferroptosis susceptibility, and glutamatergic neurotransmission, and notes that NACA enhances membrane permeability and cellular uptake compared to parent NAC.
Why it matters
The paper outlines the therapeutic evolution of NAC beyond its standard roles as an antidote and mucolytic, highlighting derivatives like NACA to address tissue distribution and pharmacokinetic limitations in redox biology.
Limits
As a narrative review, it lacks a systematic methodology, explicit inclusion criteria, or pooled quantitative effect estimates. No clinical sample sizes or statistical comparisons are reported in the abstract.
Cited by
- supports Supplementing with N-acetylcysteine (NAC) supports glutathione production and detoxification in the body.